Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset... 14 KB (1,164 words) - 07:05, 14 January 2024 |
 | being investigated as immunosuppressant therapies (e.g., otelixizumab, teplizumab) for type 1 diabetes and other autoimmune diseases. New anticancer drug... 7 KB (714 words) - 15:16, 9 April 2024 |
monoclonal antibodies with the same mechanism of action include otelixizumab, teplizumab and visilizumab. They are being investigated for the treatment of other... 2 KB (201 words) - 10:11, 10 December 2021 |
Ustekinumab IL-17A Secukinumab Cellular target CD3 Muromonab-CD3 Otelixizumab Teplizumab Visilizumab CD4 Clenoliximab Keliximab Zanolimumab CD11a Efalizumab CD18... 7 KB (299 words) - 13:45, 27 April 2024 |
 | developing the disease. In 2022 the FDA approved an intravenous injection of teplizumab to delay the progression of type 1 diabetes in those older than eight... 97 KB (10,913 words) - 20:07, 29 April 2024 |
 | CD40 autoimmune diseases and prevention of organ transplant rejection Teplizumab Tzield mab humanized CD3 Y diabetes mellitus type 1 Tepoditamab mab human... 133 KB (3,983 words) - 02:16, 19 April 2024 |
Samalizumab Satralizumab Siplizumab Spartalizumab† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab... 38 KB (4,304 words) - 20:57, 1 December 2023 |
A10BX17 Carfloglitazar A10BX18 Dorzagliatin A10XA01 Tolrestat A10XX01 Teplizumab "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis"... 6 KB (508 words) - 06:49, 20 December 2023 |
the same mechanism of action include otelixizumab (also known as TRX4), teplizumab (also known as hOKT3γ1(Ala-Ala) ), and visilizumab. They are being investigated... 13 KB (1,164 words) - 09:30, 15 March 2024 |
broad spectrum immune suppression. Antibodies specific for CD3 such as teplizumab and otelixizumab show increased specificity for T cells compared to ATG... 7 KB (766 words) - 05:29, 22 January 2024 |
Samalizumab Satralizumab Siplizumab Spartalizumab† Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab... 2 KB (87 words) - 01:28, 30 May 2023 |
response to carbohydrates consumed. In November 2022 the FDA approved Teplizumab a monoclonal antibody drug which aims to delay type 1 diabetes by reprogramming... 102 KB (12,990 words) - 09:48, 30 January 2024 |
fusions or other rearrangements Teclistamab Janssen multiple myeloma Teplizumab Provention Bio delay the onset of Stage 3 type 1 diabetes (T1D) in Stage... 34 KB (180 words) - 22:09, 8 April 2024 |
Ustekinumab IL-17A Secukinumab Cellular target CD3 Muromonab-CD3 Otelixizumab Teplizumab Visilizumab CD4 Clenoliximab Keliximab Zanolimumab CD11a Efalizumab CD18... 38 KB (2,656 words) - 12:11, 30 October 2023 |
teopranitol (INN) teoprolol (INN) Tepanil tepirindole (INN) Tepkinly teplizumab (USAN) tepoxalin (INN) teprenone (INN) teprotide (INN) teprotumumab (INN... 14 KB (658 words) - 01:01, 19 April 2024 |
 | and Type 1 Diabetes TrialNet showed that an immunotherapy drug called teplizumab delayed T1D for a median of two years for those at high risk for the disease... 31 KB (3,007 words) - 22:15, 22 January 2024 |